PTB under routine conditions, 2) the relative contribution of sputum microscopy, Xpert and clinical judgment (including radiography [CXR]) in the detection of PTB, and 3) the number of patients detected with rifampicin (RMP) resistance. Validation of diagnosis by sputum culture was beyond the scope of this operational study.
PTB under routine conditions, 2) the relative contribution of sputum microscopy, Xpert and clinical judgment (including radiography [CXR] ) in the detection of PTB, and 3) the number of patients detected with rifampicin (RMP) resistance. Validation of diagnosis by sputum culture was beyond the scope of this operational study.
METHODS
This was a cross-sectional study involving a review of NTP records and Xpert assay results. Two tertiary care hospitals (one public and one private) in Rawalpindi district were selected purposively based on their close links with the NTP and the availability of a limited number of Xpert cartridges for research purposes. All consecutive presumptive TB patients referred to the laboratories of the two hospitals for diagnostic sputum smear examination between 15 April and 30 May 2012 were informed about the study and their consent sought. Those who consented underwent an Xpert assay on the residual sputum of the initial (spot) microscopy specimen transported to the National Reference Laboratory (NRL) in addition to the routine diagnostic protocol (microscopy, CXR and clinical diagnosis). The results of the Xpert assay were reported back to the treating physicians within 24 hours of specimen collection. Technicians performing the Xpert assay and smear microscopy were blinded to each other's results.
A case of pulmonary TB was defi ned as a participant who was either smear-or Xpert-positive or judged to be a case of TB by the treating physician based on clinical assessment and CXR fi ndings. Study variables extracted into a structured tool included laboratory number, sex, age, and the results of smear microscopy, Xpert and clinical judgement (including CXR fi ndings).
Data were double-entered and validated using EpiData version 3.1 (EpiData Association, Odense, Denmark), and the numbers and relative proportions of PTB patients diagnosed by each method (sputum smear microscopy, Xpert assay and clinical judgement, including CXR) were calculated.
Ethics approval was obtained from the Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease, Paris, France.
RESULTS
Of 606 patients with presumptive TB, 307 (51%) were males, 59% were from the private hospital, and ages
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Health solu ons for the poor P akistan is one of the fi ve countries with the highest tuberculosis (TB) burden, with an annual estimated incidence of 231 per 100 000 population; it contributes 63% of the TB burden in the Eastern Mediterranean Region (EMRO). 1 Globally, TB control has been successful in terms of high treatment success rates and a consequent reduction in mortality. However, the impact on transmission of TB has not been as signifi cant as expected. Failure in timely interruption of transmission has been attributed to diagnostic and management delays; suboptimal availability of sensitive diagnostic tools has been considered as one of the obstacles in achieving early diagnosis. 2 Sputum smear microscopy, given its advantages of high specifi city, low cost and ability to identify the most infectious patients, has been a critical tool in TB control efforts. However, this test misses nearly half of all cases. 3 A new molecular test for the diagnosis of TB, Xpert ® MTB/RIF has shown great promise, with high sensitivity (73%) and specifi city (99%), and has been endorsed for use by the World Health Organization. 4 Pakistan's National TB Programme (NTP) is planning to scale up the implementation of Xpert for the diagnosis of pulmonary TB (PTB). Given the high cost per test and concerns regarding the feasibility of its implementation, the use of Xpert needs careful evaluation under routine settings before large-scale implementation.
As a pilot initiative, Xpert was used on all patients with presumptive PTB attending two health facilities in Rawalpindi, Pakistan. In this operational study we assess, among the presumptive TB cases evaluated, 1) the total number (proportion) detected as having
DISCUSSION
This is the fi rst study from Pakistan to describe the performance and shortcomings of using the Xpert assay in a programme setting. Although similar studies have been conducted in many countries under well-controlled research settings, they do not refl ect performance under routine conditions. 5, 6 This study has several implications. First, we found that Xpert detected approximately twice as many TB cases as smear microscopy alone (79 vs. 46/606), clearly demonstrating the value of Xpert in enhancing TB case fi nding. The impact on TB case fi nding would have been greater if we had been able to examine the 65 (11%) specimens lost during the process of transportation to the NRL. Future implementation models should take this into account and appropriate measures should be instituted, including strengthening the sputum collection and transport system, to avoid operational losses.
Second, clinical judgment (including good quality CXR) contributed a substantial proportion of detected cases, emphasising its continued preference among clinicians in diagnosing TB.
Third, nearly 3% of the Xpert results were invalid, and would require re-testing; this needs to be taken into account by the programme managers during planning for procurement and supply chain management. It is interesting to note that there were three patients who were smear-positive but Xpert-negative; although the exact reason is not clear, it could be due to non-tuberculous mycobacteria.
The study had some important limitations. First, the almost double yield of Xpert might be due to suboptimal quality of the microscopy. As we did not collect reliable data on microscopy quality, we are uncertain about the incremental yield of the Xpert assay. Second, as this was operational research conducted under routine conditions, we could not use a gold standard to confi rm the diagnosis of PTB and RMP resistance, and hence we are unable to comment on the sensitivity and specifi city of each tool used. Third, although cost is an important consideration in the decision to scale up Xpert, we did not include it in this study, and it is a topic for future research. En plus d'un protocole de diagnostic de routine (examen microscopique des frottis, cliché thoracique et évaluation clinique), on a offert Xpert ® MTB/RIF à des patients consécutifs suspects de tuberculose (TB) qui présentaient à deux hôpitaux du Pakistan au cours de la période avril-mai 2012. Nous avons évalué la contribution relative de chaque outil à la détection de la TB pulmonaire dans les conditions de routine. Sur 606 participants, 121 (20%) ont été diagnostiqués comme TB pulmonaire : 46 (38%) par l'examen microscopique, 38
